BioSpecifics Technologies Corporation to Present at Rodman & Renshaw 10th Annual Healthcare Conference

LYNBROOK, N.Y., Nov. 7 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. , a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 12, 2008, at 10:20am ET at the New York Palace Hotel in New York, NY.

A live webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq14/bstc.ob. The presentation will be archived for 90 days.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis). It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. Positive top line results from the Phase III clinical trials with XIAFLEX(TM) for treatment of Dupuytren's disease were released in June 2008. More information about the company may be found on its website at www.biospecifics.com.

CONTACT: Thomas L. Wegman, President of BioSpecifics Technologies Corp.,
+1-516-593-7000, thomas_wegman@biospecifics.com

Web site: http://www.biospecifics.com/
http://www.wsw.com/webcast/rrshq14/bstc.ob/